Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:Q06643 (non-Hodgkin's lymphoma)
 11,307 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Arbekacin (ABK) was administered to 17 patients with MRSA infections that complicated underlying hematopoietic disorders, and the efficacy and safety were evaluated. The underlying diseases included acute myelocytic leukemia (8 cases), acute lymphocytic leukemia (1) myelodysplastic syndrome (3), chronic myelocytic leukemia (1), non-Hodgkin's lymphoma (2), Hodgkin's disease (1) and adult T cell leukemia (1). The infections consisted of septicemia (5 cases), pneumonia (4), upper respiratory tract infections (6) and urinary tract infections (2). ABK was administered by i.v. drip infusion in daily doses of 150-200 mg, given in two divided dosages. The therapeutic efficacies were: excellent in 2 (2 septicemias), good in 7 (1 septicemia, 4 upper respiratory infections, 2 urinary tract infections), fair in 2 (septicemia and pneumonia) and poor in 6 (1 septicemia, 3 pneumonias, 2 upper respiratory infections). As a side effect, reversible renal dysfunction was detected in four cases. Causative bacteria were isolated from six cases. They were all coagulase type II and MIC's of ABK were from 0.25 microgram/ml to 4.0 micrograms/ml. Arbekacin therapy was found to be effective even in patients with hematopoietic disorders accompanied by MRSA infections.
 ...
PMID:[Clinical efficacy of arbekacin on MRSA infections with hematopoietic disorders. The Hanshin Study Group of Hematopoietic Disorders and Infections]. 807 85

Recently, the progress of chemotherapy has improved the clinical outcome of chemotherapy for hematopoietic malignancies considerably. However, the incidence of MRSA infections has increased in patients with hematopoietic malignancies, since preventive, multi-drug administration of antibiotics is frequently used in these patients. Moreover, patients with hematopoietic malignancies complicated by MRSA pneumonia have a poor prognosis. We examined lymphocyte subpopulations in bronchoalveolar lavage fluid (BALF) in MRSA pneumonia-complicated patients with hematopoietic malignancies and studied their relationship with the clinical features. We also discuss the cause of their poor prognosis. Of 223 patients with hematopoietic malignancies, 18 (8.1%) were complicated by MRSA pneumonia. Many of those patients had lymphoid malignancies. MRSA pneumonia occurred when neutrophil count was decreased. Most patients had been treated with chemotherapy containing anticancer drugs or with corticosteroid therapy. They had also been treated with third generation cefem antibiotics. We studied lymphocyte subsets in BALF in MRSA pneumonia-complicated patients with non-Hodgkin's lymphoma (NHL) and observed the local changes of the pulmonary immunological system due to NHL itself and due to anti-lymphoma chemotherapy. Our findings suggest the possibility that these immunological changes may play a role in the susceptibility to MRSA pneumonia.
 ...
PMID:[Studies on MRSA pneumonia as a complication of hematopoietic malignancies]. 811 69